rhIL-15

also known as IL-15 · recombinant human interleukin-15 · Interleukin-15

Developed for: neuroblastoma · renal cell carcinoma · anaplastic large cell lymphoma · B-cell neoplasm · brain cancer · carcinoma · childhood malignant neoplasm · clear cell renal carcinoma
+13 more
· cutaneous melanoma · head and neck squamous cell carcinoma · lymphoid leukemia · lymphoma · melanoma · metastatic neoplasm · mycosis fungoides · non-small cell lung carcinoma · peripheral T-cell lymphoma, not otherwise specified · refractory malignant neoplasm · sarcoma · Sezary syndrome · skin carcinoma
Investigated by: National Cancer Institute (NCI)

Trials 9

today NCT06995872 · Ph 1 NCT04150562 · Ph 2 NCT03759184 · Ph 1 NCT03905135 · Ph 1 NCT03388632 · Ph 1 NCT01875601 · Ph 1 NCT01727076 · Ph 1 NCT01572493 · Ph 1 NCT01021059 · Ph 1

2010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 18 trials
Phase 1	NCT06995872	Oct 2025 → Jun 2028 expected	neuroblastoma	National Cancer Institute (NCI)	Recruiting	No outcome recorded
Phase 1	NCT03759184	Jul → Dec 2019	B-cell neoplasm, lymphoid leukemia	National Cancer Institute (NCI)	Terminated	No outcome recorded
Phase 1	NCT03905135	Jun 2019 → Mar 2021	Sezary syndrome, anaplastic large cell lymphoma, mycosis fungoides, peripheral T-cell lymphoma, not otherwise specified	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT03388632	Feb 2018 → Nov 2024	metastatic neoplasm, refractory malignant neoplasm	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT01875601	Jun 2013 → Sep 2015	brain cancer, childhood malignant neoplasm, neuroblastoma, sarcoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT01727076	Feb 2013 → Jun 2016	cutaneous melanoma, head and neck squamous cell carcinoma, non-small cell lung carcinoma, renal cell carcinoma +1	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT01572493	Apr 2012 → Jun 2019	carcinoma, lymphoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT01021059	Nov 2009 → May 2013	melanoma, renal cell carcinoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 21 trial
Phase 2	NCT04150562	May 2020 → Jul 2021	clear cell renal carcinoma	National Cancer Institute (NCI)	Terminated	No outcome recorded Stop: Enrollment

Press releases naming this drug 1 release

Date	Issuer	Release
2021-09-21	Nektar Therapeutics	Nektar Announces New Clinical Collaboration with Merck KGaA Darmstadt, Germany and Pfizer Inc. to Combine NKTR-255, a Novel Interleukin-15 Agonist, with Avelumab in the JAVELIN Bladder Medley Study nektar.com ↗

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 12 sources stand behind the page.

Field	Value	Cited text
Known as	rhIL15	“The first-in-human clinical trial with human bolus intravenous infusion IL15 (rhIL15) was limited by treatment-associated toxicity.” PMID 31142503 ↗ May 2019 10 “Our initial effort with intravenous bolus recombinant human interleukin-15 (rhIL-15) was limited by postinfusional reactions.” PMID 33883258 ↗ Apr 2021 “Recombinant human interleukin-15 (rhIL-15) is a substance that is naturally produced in the body” NCT01021059 ↗ “Recombinant human interleukin-15 (rhIL-15)” NCT01875601 ↗ NCT01021059 ↗ NCT03388632 ↗ NCT01572493 ↗ NCT03759184 ↗ NCT04150562 ↗ NCT06995872 ↗ NCT03905135 ↗
Known as	IL-15	“Interleukin-15 (IL-15) will be administered by continuous intravenous infusion in a dose-escalation fashion with a starting dose level of 1 mcg/kg/day, a second dose level of 2...” NCT03905135 ↗ 4 “Recombinant human Interleukin-15 (rhIL-15) is a stimulatory cytokine that promotes the differentiation and activation of NK cells, monocytes, and long-term cluster of...” NCT03759184 ↗ “The first-in-human clinical trial with human bolus intravenous infusion IL15 (rhIL15) was limited by treatment-associated toxicity.” PMID 31142503 ↗ May 2019 “Recombinant human interleukin-15 (rhIL-15) is a substance that is naturally produced in the body” NCT01021059 ↗ “recombinant human interleukin (IL)-15 (rhIL-15)” NCT06995872 ↗
Known as	Interleukin-15	“Interleukin-15 (IL-15) will be administered by continuous intravenous infusion in a dose-escalation fashion with a starting dose level of 1 mcg/kg/day, a second dose level of 2...” NCT03905135 ↗ 2 “Recombinant human Interleukin-15 (rhIL-15) is a stimulatory cytokine that promotes the differentiation and activation of NK cells, monocytes, and long-term cluster of...” NCT03759184 ↗ “Our initial effort with intravenous bolus recombinant human interleukin-15 (rhIL-15) was limited by postinfusional reactions.” PMID 33883258 ↗ Apr 2021
Known as	recombinant human interleukin-15	“Recombinant human interleukin-15 (rhIL-15) is a substance that is naturally produced in the body” NCT01021059 ↗ 4 “Recombinant human Interleukin-15” NCT03905135 ↗ “Recombinant human Interleukin-15” NCT01572493 ↗ NCT01727076 ↗ NCT01875601 ↗
Action	Activate	“IL-15 has significant potential in cancer immunotherapy as an activator of antitumor CD8 T and natural killer (NK) cells.” PMID 25403209 ↗ Nov 2014
Modality	Protein / enzyme biologic	“Escherichia coli-produced rhIL-15.” PMID 25403209 ↗ Nov 2014
Route	Intravenous	“rhIL-15 will be given intravenously once a day for 12 consecutive days” NCT01021059 ↗